Madrigal Stock Today

MDGL
 Stock
  

USD 67.15  0.65  0.98%   

Market Performance
1 of 100
Odds Of Distress
Less than 48
Madrigal Pharmaceuticals is selling for 67.15 as of the 27th of November 2022. This is a 0.98 percent up since the beginning of the trading day. The stock's lowest day price was 66.02. Madrigal Pharmaceuticals has 48 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Madrigal Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2021 and ending today, the 27th of November 2022. Click here to learn more.
CUSIP
87162T206
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of February 2007
Category
Healthcare
Classification
Health Care
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. The company has 17.1 M outstanding shares of which 1.55 M shares are now shorted by private and institutional investors with about 5.64 trading days to cover. More on Madrigal Pharmaceuticals
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Madrigal Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Madrigal Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Madrigal Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Madrigal Pharmaceuticals has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 147 K. Net Loss for the year was (255.9 M) with profit before overhead, payroll, taxes, and interest of 10.31 M.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (200.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are owned by institutional investors
President CEO, DirectorChen Schor
Average Analyst Recommendation
Analysts covering Madrigal Pharmaceuticals report their recommendations after researching Madrigal Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Madrigal Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Madrigal Pharmaceuticals. The Madrigal consensus assessment is calculated by taking the average forecast from all of the analysts covering Madrigal Pharmaceuticals.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Madrigal Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Madrigal Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted17.8 M16.5 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares17.8 M16.5 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities82.9 M76.8 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities83.3 M77.2 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Total Debt818 K797 K
Fairly Up
Decreasing
Slightly volatile
Asset Turnover0.00240.0023
Fairly Up
Decreasing
Slightly volatile
Current Assets219.1 M271.7 M
Significantly Down
Increasing
Slightly volatile
Total Assets220.5 M273.3 M
Significantly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Madrigal Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Madrigal Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Madrigal Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Madrigal Pharmaceuticals' financial leverage. It provides some insight into what part of Madrigal Pharmaceuticals' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Madrigal Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Madrigal Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Madrigal Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 49.73 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Madrigal Pharmaceuticals has a current ratio of 2.5, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Madrigal Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Madrigal Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Madrigal Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Madrigal to invest in growth at high rates of return. When we think about Madrigal Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(188.76 Million)
Madrigal Pharmaceuticals (MDGL) is traded on NASDAQ Exchange in USA and employs 71 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Madrigal Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Madrigal Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Madrigal Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 17.1 M outstanding shares of which 1.55 M shares are now shorted by private and institutional investors with about 5.64 trading days to cover. Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (200.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Check Madrigal Pharmaceuticals Probability Of Bankruptcy
Ownership
Madrigal Pharmaceuticals maintains a total of seventeen million one hundred thousand outstanding shares. The majority of Madrigal Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Madrigal Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Madrigal Pharmaceuticals. Please pay attention to any change in the institutional holdings of Madrigal Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Madrigal Ownership Details

Madrigal Stock Price Odds Analysis

Based on a normal probability distribution, the odds of Madrigal Pharmaceuticals jumping above the current price in 90 days from now is about 66.12%. The Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1388. This indicates Madrigal Pharmaceuticals market returns are highly reactive to returns on the market. As the market goes up or down, Madrigal Pharmaceuticals is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Madrigal Pharmaceuticals is significantly underperforming DOW.
  Odds Below 67.15HorizonTargetOdds Above 67.15
33.67%90 days
 67.15 
66.12%
Based on a normal probability distribution, the odds of Madrigal Pharmaceuticals to move above the current price in 90 days from now is about 66.12 (This Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Stock to fall within a particular range of prices over 90 days) .

Madrigal Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Madrigal Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Madrigal Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Madrigal Pharmaceuticals' value.
InstituionSecurity TypeTotal SharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.6 K114 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares1.6 K160 K
View Madrigal Pharmaceuticals Diagnostics

Madrigal Pharmaceuticals Historical Income Statement

Madrigal Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Madrigal's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Madrigal Pharmaceuticals revenue and expense. Madrigal Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Madrigal Pharmaceuticals Selling General and Administrative Expense is relatively stable at the moment as compared to the past year. The company's current value of Selling General and Administrative Expense is estimated at 40.26 Million. Weighted Average Shares is expected to hike to about 17.8 M this year, although the value of Earning Before Interest and Taxes EBIT will most likely fall to (248.2 M). View More Fundamentals

Madrigal Stock Against Markets

Picking the right benchmark for Madrigal Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Madrigal Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Madrigal Pharmaceuticals is critical whether you are bullish or bearish towards Madrigal Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Madrigal Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Madrigal Pharmaceuticals Corporate Directors

Madrigal Pharmaceuticals corporate directors refer to members of a Madrigal Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Madrigal Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Madrigal Pharmaceuticals' board members must vote for the resolution. The Madrigal Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Frederick Craves - Lead Independent DirectorProfile
Paul Friedman - Independent DirectorProfile
David Milligan - Independent DirectorProfile
Robert Wilson - Independent DirectorProfile

Invested in Madrigal Pharmaceuticals?

The danger of trading Madrigal Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Madrigal Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Madrigal Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Madrigal Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Correlation Analysis. Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Madrigal Stock analysis

When running Madrigal Pharmaceuticals price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.1 B
Return On Assets
(0.74) 
Return On Equity
(2.23) 
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Madrigal Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.